Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2024
Subject: Approval of settlement regarding shareholder derivative litigation.
Key Financial Metrics
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a specific legal settlement cost.
- Legal Settlement Cost: $950,000 (attorneys' fees and expenses).
Material Changes
The primary material event is the final resolution of the In re Myriad Genetics, Inc. Stockholder Derivative Litigation and the related federal action. On November 26, 2024, the Court of Chancery of the State of Delaware approved the global stipulation of settlement previously agreed upon by the parties on April 30, 2024.
Outlook, Risks, and Contingencies
Settlement Terms:
- Corporate Governance: The Company agreed to adopt or implement certain corporate governance reforms.
- Liability: The settlement contains no admission of liability, wrongdoing, or responsibility by any party.
- Dismissal: The consolidated Derivative Action was dismissed with prejudice. The federal derivative plaintiff is ordered to seek prompt dismissal with prejudice of the Federal Derivative Action.
- Payment: The Company is ordered to pay $950,000 in attorneys' fees and expenses.
Risks: The filing notes that the information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference in other filings.
Investor Verification Checklist
- Verify the impact of the $950,000 legal expense on the Company's current quarter or fiscal year financial statements.
- Review the specific details of the "corporate governance reforms" the Company agreed to implement as part of the settlement.
- Confirm the status of the Federal Derivative Action to ensure it has been dismissed with prejudice as ordered.